ICA Group Wealth Management’s Indivior Pharmaceuticals INDV Stock Holding History

ICA Group Wealth Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$2.42K	Buy	+150	New	+$2.71K	﹤0.01%	662

Other funds holding INDV

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ICA Group Wealth Management's INDV Position: Q2 2024 in Review

ICA Group Wealth Management opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2024: 150 shares worth $2.42K. The stake represents ﹤0.01% of the portfolio and ranks #662 among its holdings.

99 funds tracked by Wall St. Rank hold INDV as of Q2 2024.

ICA Group Wealth Management held 150 shares of Indivior Pharmaceuticals worth $2.42K as of Q2 2024.
Indivior Pharmaceuticals was a new ICA Group Wealth Management position in Q2 2024.
Indivior Pharmaceuticals made up ﹤0.01% of ICA Group Wealth Management's portfolio in Q2 2024, its #662 holding.
99 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2024.

Based on ICA Group Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.